BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 22180724)

  • 1. Hepatitis C Viral Kinetics in the Era of Direct Acting Antiviral Agents and IL28B.
    Dahari H; Guedj J; Perelson AS; Layden TJ
    Curr Hepat Rep; 2011 Jul; 10(3):214-227. PubMed ID: 22180724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of IL28B for chronic hepatitis C treatment toward personalized medicine.
    Matsuura K; Watanabe T; Tanaka Y
    J Gastroenterol Hepatol; 2014 Feb; 29(2):241-9. PubMed ID: 24325405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced ITPase activity and favorable IL28B genetic variant protect against ribavirin-induced anemia in interferon-free regimens.
    Vasanthakumar A; Davis JW; Abunimeh M; Söderholm J; Zha J; Dumas EO; Cohen DE; Waring JF; Lagging M
    PLoS One; 2018; 13(5):e0198296. PubMed ID: 29851985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoantibodies to cytoplasmic rods and rings in patients with hepatitis C virus infection treated with direct-acting antivirals: The role of prior treatment with interferon plus ribavirin.
    Alsius M; Ferri MJ; Buxó M; López C; Serra I; Queralt X; Acero D
    Gastroenterol Hepatol; 2019 Feb; 42(2):82-89. PubMed ID: 30446175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphism Near the Interleukin-28B Gene and Anti-Hepatitis C Viral Response.
    Asahina Y; Nakagawa M; Kakinuma S; Watanabe M
    J Clin Transl Hepatol; 2013 Sep; 1(1):39-44. PubMed ID: 26357605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A decade of hepatitis C at the University of Cape Town/Groote Schuur Hospital Liver Clinic, South Africa, in the pre-direct-acting antivirals era.
    Nordien R; Sonderup MW; Spearman CW
    S Afr Med J; 2020 Jan; 110(2):106-111. PubMed ID: 32657679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of IL28B genotype on hepatitis B and C virus infection.
    Stättermayer AF; Ferenci P
    Curr Opin Virol; 2015 Oct; 14():50-5. PubMed ID: 26284971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C.
    Fukuhara T; Taketomi A; Motomura T; Okano S; Ninomiya A; Abe T; Uchiyama H; Soejima Y; Shirabe K; Matsuura Y; Maehara Y
    Gastroenterology; 2010 Nov; 139(5):1577-85, 1585.e1-3. PubMed ID: 20708617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C virus kinetics by administration of pegylated interferon-α in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene.
    Watanabe T; Sugauchi F; Tanaka Y; Matsuura K; Yatsuhashi H; Murakami S; Iijima S; Iio E; Sugiyama M; Shimada T; Kakuni M; Kohara M; Mizokami M
    Gut; 2013 Sep; 62(9):1340-6. PubMed ID: 23135762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors.
    Kurosaki M; Tanaka Y; Nishida N; Sakamoto N; Enomoto N; Honda M; Sugiyama M; Matsuura K; Sugauchi F; Asahina Y; Nakagawa M; Watanabe M; Sakamoto M; Maekawa S; Sakai A; Kaneko S; Ito K; Masaki N; Tokunaga K; Izumi N; Mizokami M
    J Hepatol; 2011 Mar; 54(3):439-48. PubMed ID: 21129805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LDLr genotype modifies the impact of IL28B on HCV viral kinetics after the first weeks of treatment with PEG-IFN/RBV in HIV/HCV patients.
    Rivero-Juarez A; Camacho A; Caruz A; Neukam K; Gonzalez R; Di Lello FA; Perez-Camacho I; Mesa P; Torre-Cisneros J; Peña J; Pineda JA; Rivero A
    AIDS; 2012 May; 26(8):1009-15. PubMed ID: 22382144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
    Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
    J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response.
    Neukam K; Barreiro P; Rivero-Juárez A; Caruz A; Mira JA; Camacho A; Macías J; Rivero A; Soriano V; Pineda JA
    J Infect; 2013 Jul; 67(1):59-64. PubMed ID: 23542783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.
    Itokawa N; Atsukawa M; Tsubota A; Kondo C; Hashimoto S; Fukuda T; Matsushita Y; Kidokoro H; Kobayashi T; Narahara Y; Nakatsuka K; Kanazawa H; Iwakiri K; Sakamoto C
    J Gastroenterol Hepatol; 2013 Mar; 28(3):443-9. PubMed ID: 23173698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Impact of Direct-Acting Antivirals in the Hepatitis C-Sustained Viral Response in Human Immunodeficiency Virus-Infected Patients With Ongoing Barriers to Care.
    Cachay ER; Wyles D; Hill L; Ballard C; Torriani F; Colwell B; Kuo A; Schooley R; Mathews CW
    Open Forum Infect Dis; 2015 Dec; 2(4):ofv168. PubMed ID: 26697509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of ribavirin in direct acting antiviral drug regimens for chronic hepatitis C.
    Clark V; Nelson DR
    Liver Int; 2012 Feb; 32 Suppl 1(0 1):103-7. PubMed ID: 22212579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infection.
    Sakhaee F; Ghazanfari M; Vaziri F; Jamnani FR; Davari M; Gharibzadeh S; Fateh R; Abdolrahimi F; Dizaji SP; Fateh A; Siadat SD
    Infect Genet Evol; 2017 Oct; 54():330-337. PubMed ID: 28739427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Interleukin 28B Polymorphism with Clearance of Hepatitis C Virus: A Mini Review.
    Shaheen M; Afzal S; Khubaib B; Amin I; Shahid M; Idrees M
    Crit Rev Eukaryot Gene Expr; 2020; 30(3):223-229. PubMed ID: 32749108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The hepatitis C revolution part 1: antiviral treatment options.
    Thiagarajan P; Ryder SD
    Curr Opin Infect Dis; 2015 Dec; 28(6):563-71. PubMed ID: 26524328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.
    Bailly F; Pradat P; Virlogeux V; Zoulim F
    Dig Dis; 2015; 33(4):613-23. PubMed ID: 26159282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.